Diagnostic Assistance Solution for Big 3 Chest Disease

Advanced AI-Powered Analysis for

Lung Nodules, COPD, and CAC

aview identifies small lung nodules that can develop into lung cancer, and quickly detects damage
to the lung parenchyma, calcification of the coronary arteries. It is useful for related examinations and follow-up observations
by simultaneously detecting and analyzing chest diseases.

aview LCS PLUS | Lung Cancer Screening

Lung Cancer Screening

aview LCS PLUS | Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

aview LCS PLUS | Coronary artery Calcium scoring

Coronary artery Calcium scoring

Conformity Certifications

  • MFDS

    Republic of Korea

  • FDA

    United States of America

  • PMDA

    Japan

  • TFDA

    Taiwan

  • CE

    Europe

  • TGA

    Australia

  • HSA

    Singapore

  • ANVISA

    Brazil

  • HC

    Canada

Automated Detection and Analysis Solution for
Lung Nodules, COPD, CAC

aview LCS PLUS can be also used as three individual products :
COPD, LCS and CAC

Emphysema

Emphysema Analysis

Translates low-dose chest CT images to analyze emphysema and automatically report the results. Converts and Analyzes emphysema with Low-dose CT images and generate automated comprehensive report.

aview LCS PLUS | Emphysema Analysis

Lung Nodule

Lung Nodules Detection and Analysis

Convert low-dose chest CT images to analyze lung nodules and automatically report the results.

aview LCS PLUS | Lung Nodules Detection and Analysis

Coronary Artery Calcium

Detection of calcium in the coronary artery

Convert low-dose chest CT images to find calcification
in the coronary artery and automatically
reports the results.

aview LCS PLUS | Detection of calcium in the coronary artery

Supply of global lung cancer screening projects

aview is adopted as a lung cancer screening solution in five countries: South Korea, Germany, Italy, and five European countries

aview LCS PLUS | Supply of global lung cancer screening projects aview LCS PLUS | Supply of global lung cancer screening projects aview LCS PLUS | Supply of global lung cancer screening projects aview LCS PLUS | Supply of global lung cancer screening projects aview LCS PLUS | Supply of global lung cancer screening projects
South Korea's lung cancer screening project

K-Lucas

South Korea's lung cancer screening project

  • Sole AI solution provider for 7 consecutive years
  • Annually screen 200,000 High-Risk Individuals for Lung Cancer.
  • Comprehensive Cloud-based Quality Management Service
Lung Cancer Screening Study in Germany

HANSE

Lung Cancer Screening Study in Germany

  • three hospitals in two states

    Hannover Medical School (MHH)

    The University Medical Center Schleswig- Holstein, Lübeck Campus (UKSH)

    LungenClinic Grosshansdorf

  • Two-Year Lung Cancer Screening for 5,000 Individuals
Italian Lung Screening Project

ILSP

Italian Lung Screening Project

  • Milan National Cancer Center
  • 18 hospitals in 18 states
  • Two-Year Lung Cancer Screening for 5,000 Individuals
Lung cancer screening project in five European countries

4-In-The-Lung-Run

Lung cancer screening project in five European countries

  • eight hospitals in Europe

    Netherlands, Germany, Spain, Italy and France

  • Lung Cancer Screening for 26,000 Individuals Over Four Years

Publications

Refer to the following
research papers

These contents represent summaries of scientific
publications and are unrelated to any form of advertising.

  • text icon

    Lung cancer is the cause of many deaths that could have been avoided if the disease had been detected at an early stage. Due to the heavy workload on the healthcare system, shortages of specialists, and expensive equipment, new solutions are needed to support the work of the hospitals. aview LCS PLUS is designed for the analysis of lung cancer, COPD, and CVD. By applying AI to disease detection, it can alleviate the strain on healthcare systems and ultimately save lives.

    Joanna Bidzinska and Edyta Szurowska. “See Lung Cancer with an AI” Cancers.

  • text icon

    The study aims to evaluate the use of automated coronary artery calcium (CAC) and quantitative emphysema (LAA) measurements in predicting mortality and lung cancer incidence during lung cancer screening. Additionally, it seeks to understand the relationships between LAA, CAC, forced expiratory value in 1 second (FEV1), and the ability of LAA to detect airflow obstruction. The LDCT images were analyzed using fully automated AI software (aview LCS PLUS, Coreline Soft) In a 6-year monitoring study involving 4,098 participants, the results revealed significant associations between increased age, male gender, a higher number of pack-years of smoking, and self-reported COPD with all mortality outcomes. LDCT biomarkers negatively correlated with FEV1, with %LAA enabling the identification of airflow obstruction with moderate discriminative ability.

    Balbi M, Sabia F, Ledda RE, et al. “Automated Coronary Artery Calcium and Quantitative Emphysema in Lung Cancer Screening: Association With Mortality, Lung Cancer Incidence, and Airflow Obstruction.” J Thorac Imaging. 2023;38(4):W52-W63.